2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4497 Evolving patient selection, toxicity, and survival across eight years of axicabtagene ciloleucel therapy for large B-cell lymphoma

Justin Abraham Kahla, MD, John Cursio, PhD2, Eli P. Darnell3, Justin Kline, MD4, Alexandra Ewa Rojek, MD5, Michael R. Bishop, MD6, Peter Riedell, MD7
1 The University of Chicago, Chicago, Illinois, United States
2 The University of Chicago, Chicago, Illinois, United States
3 The University of Chicago, Chicago, Illinois, United States
4 The University of Chicago, Chicago, Illinois, United States
5 The University of Chicago, Chicago, Illinois, United States
6 The University of Chicago, Chicago, Illinois, United States
7 The University of Chicago, Chicago, Illinois, United States

Introduction CD19-directed CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (LBCL) was first approved in the US in 2017, and reported outcomes have improved over time. These gains are attributed to advances in patient selection, bridging strategies, toxicity management, and accumulated institutional experience, yet their relative contributions remain undefined. We compared outcomes among patients receiving axicabtagene ciloleucel (axi-cel) in the years immediately following commercialization with those treated in a contemporary era, to characterize how patient selection and management evolved with institutional experience and to identify determinants of improved outcomes.

Methods We analyzed 72 consecutive LBCL patients who underwent leukapheresis with intent to receive axi-cel at the University of Chicago (2017-2025). Patients were split into two eras: Era 1, 11/01/2017-6/5/2019 (n=44); Era 2, 6/6/2019-6/01/2025 (n=28). This cut point separates initial commercialization from a contemporary era in which alternative CD19-directed treatments and novel salvage options became available. Continuous variables were compared by Wilcoxon rank-sum test; categorical variables by chi-square or Fisher's exact test. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier and compared by log-rank; non-relapse mortality (NRM) by competing risks. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded per ASTCT consensus criteria. Toxicity and response are reported among infused patients (n=39, n=27).

Results Baseline characteristics were similar, including median age (60y vs 54y), sex, ECOG, HCT-CI score, median Charlson Comorbidity Index score, and IPI. Era 1 was more heavily pretreated (median 3 vs 2 prior lines, p=0.005), with a higher incidence of prior CNS involvement (59.1% vs 25.0%, p=0.005), and higher median LDH at lymphodepletion (378 U/L vs 278 U/L, p=0.02). The proportion of patients refractory to the most recent line of therapy did not differ (36.4% vs 35.6%, p=0.95).

Bridging therapy use was similar between eras (65.9% vs 53.6%, p=0.33), but its composition diverged. Among bridged patients, steroid-only (27.6% vs 6.7%, p=0.13) and chemotherapy-based bridging (41.4% vs 20.0%, p=0.19) were numerically more common in Era 1. Polatuzumab vedotin-based bridging, unavailable in the earlier era, was used in 53.3% of cases in Era 2. Axi-cel infusion occurred in 39/44 (88.6%) and 27/28 (96.4%) of patients in Eras 1 and 2, respectively (p=0.39). All infused patients received lymphodepletion with fludarabine/cyclophosphamide.

Any grade CRS was similar between eras (92.3% vs 85.2%, p=0.43), but grade ≥2 CRS fell markedly (61.5% vs 22.2%, p=0.002), with no grade ≥3 CRS in Era 2. Any grade ICANS occurred less frequently in Era 2 (66.7% vs 25.9%, p=0.01) as did grade ≥2 ICANS (51.3% vs 18.5%, p=0.007), while grade ≥3 ICANS was not significantly different. Time to onset and duration of CRS and ICANS did not differ. Tocilizumab use (84.6% vs 77.8%, p=0.53) and overall steroid exposure (59.0% vs 74.1%, p=0.29) were unchanged. Hospital stay shortened (median 17 vs 15 days, p=0.03), and ICU admission declined (33.3% vs 11.1%, p=0.046) in the modern era.

Median follow-up was 310 vs 607 days. Day 30 overall response rate improved (48.7% vs 77.8%, p=0.02) without a change in complete response rate (28.2% vs 33.3%, p=0.79). One-year PFS was similar between eras (25.6% vs 26.5%, p=0.36), while one-year OS was improved in Era 2 (28.2% vs 56.6%, p=0.011). One-year NRM was 5.1% vs 7.5% (HR 0.68, 0.10-4.57, p=0.69). Among patients who died, lymphoma was the cause in 82.1% of Era 1 but only 45.5% of Era 2 (p=0.044); infection accounted for 7.1% vs 36.4% of deaths (p=0.042).

Conclusions Contemporary axi-cel recipients experienced less severe CRS and ICANS, shorter hospitalizations, and improved OS. We speculate that lower disease burden, reflected in fewer prior lines of therapy and lower LDH, underlies the attenuation of toxicity. Critically, PFS and CR were unchanged, suggesting that improved OS in Era 2 likely derives from earlier-line CAR T-cell therapy and effective post-progression therapy. Infection accounted for a larger share of deaths in Era 2 as lymphoma-related mortality declined, suggesting that optimizing antimicrobial prophylaxis and immune reconstitution may further reduce NRM.

Justin Abraham Kahla, MD: No relevant conflicts of interest to declare.